A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

RJMty19 (CD19-CAR-DNT cells)

Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.

Trial Locations (4)

100044

Peking University People's Hospital, Beijing

200001

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

200433

Changhai Hospital, Shanghai

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

Changhai Hospital

OTHER

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

lead

Guangdong Ruishun Biotech Co., Ltd

INDUSTRY

NCT06340490 - A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter